

| | | | | | |
|--|---|----|--------------------------|------------------------|------------------------|
| Substitute for form 1449-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | 1 | of | 1 | Application Number | 10/644,579-Conf. #5200 |
| | | | | Filing Date | August 20, 2003 |
| | | | | First Named Inventor | Connie Sanchez |
| | | | | Art Unit | 1617 |
| | | | | Examiner Name | Y. S. Chong |
| | | | | Attorney Docket Number | 05432/100M919-US1 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CA | Mischoulon et al., "Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians", Can. J. Psychiatry, 45, 476-481 (2000) | |
| | CB | Posternak et al., "Switching Versus Augmentation: A prospective, Naturalistic Comparison in Depressed, Treatment-Resistant Patients", J. Clin Psychiatry, 62, 135-142 (2001) | |
| | CC | Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression by the Committee for Proprietary medicinal Products (CPMP) Dated April 25, 2002 | |
| | CD | Approval Package of the Center for Drug Evaluation and Research for Citalopram Hydrobromide (trade name: Celexa) dated July 17, 1998 including the Approval Letter, the Approvable Letter and the Final Printed Labelling specification, said documents having been made available to the public by the FDA on July 20, 1998. | |
| | CE | Merck Manual of Diagnostics, Home Edition, pp 438-447 (1997). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.